KRYS
Price
$154.05
Change
-$0.33 (-0.21%)
Updated
Sep 17 closing price
Capitalization
4.47B
53 days until earnings call
VRDN
Price
$18.62
Change
-$0.04 (-0.21%)
Updated
Sep 17 closing price
Capitalization
1.52B
61 days until earnings call
Interact to see
Advertisement

KRYS vs VRDN

Header iconKRYS vs VRDN Comparison
Open Charts KRYS vs VRDNBanner chart's image
Krystal Biotech
Price$154.05
Change-$0.33 (-0.21%)
Volume$280.63K
Capitalization4.47B
Viridian Therapeutics
Price$18.62
Change-$0.04 (-0.21%)
Volume$421.35K
Capitalization1.52B
KRYS vs VRDN Comparison Chart in %
Loading...
KRYS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
VRDN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
KRYS vs. VRDN commentary
Sep 18, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is KRYS is a StrongBuy and VRDN is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Sep 18, 2025
Stock price -- (KRYS: $154.13 vs. VRDN: $18.62)
Brand notoriety: KRYS and VRDN are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: KRYS: 80% vs. VRDN: 55%
Market capitalization -- KRYS: $4.47B vs. VRDN: $1.52B
KRYS [@Biotechnology] is valued at $4.47B. VRDN’s [@Biotechnology] market capitalization is $1.52B. The market cap for tickers in the [@Biotechnology] industry ranges from $100.34B to $0. The average market capitalization across the [@Biotechnology] industry is $1.89B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

KRYS’s FA Score shows that 0 FA rating(s) are green whileVRDN’s FA Score has 0 green FA rating(s).

  • KRYS’s FA Score: 0 green, 5 red.
  • VRDN’s FA Score: 0 green, 5 red.
According to our system of comparison, KRYS is a better buy in the long-term than VRDN.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

KRYS’s TA Score shows that 7 TA indicator(s) are bullish while VRDN’s TA Score has 4 bullish TA indicator(s).

  • KRYS’s TA Score: 7 bullish, 2 bearish.
  • VRDN’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, KRYS is a better buy in the short-term than VRDN.

Price Growth

KRYS (@Biotechnology) experienced а +12.12% price change this week, while VRDN (@Biotechnology) price change was -6.05% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +1.28%. For the same industry, the average monthly price growth was +6.08%, and the average quarterly price growth was +34.58%.

Reported Earning Dates

KRYS is expected to report earnings on Nov 10, 2025.

VRDN is expected to report earnings on Nov 18, 2025.

Industries' Descriptions

@Biotechnology (+1.28% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
KRYS($4.47B) has a higher market cap than VRDN($1.52B). KRYS YTD gains are higher at: -1.618 vs. VRDN (-2.869). KRYS has higher annual earnings (EBITDA): 158M vs. VRDN (-340.62M). KRYS has more cash in the bank: 682M vs. VRDN (563M). KRYS has less debt than VRDN: KRYS (9.68M) vs VRDN (21.3M). KRYS has higher revenues than VRDN: KRYS (359M) vs VRDN (305K).
KRYSVRDNKRYS / VRDN
Capitalization4.47B1.52B293%
EBITDA158M-340.62M-46%
Gain YTD-1.618-2.86956%
P/E Ratio31.33N/A-
Revenue359M305K117,705%
Total Cash682M563M121%
Total Debt9.68M21.3M45%
FUNDAMENTALS RATINGS
KRYS vs VRDN: Fundamental Ratings
KRYS
VRDN
OUTLOOK RATING
1..100
6665
VALUATION
overvalued / fair valued / undervalued
1..100
65
Fair valued
95
Overvalued
PROFIT vs RISK RATING
1..100
3993
SMR RATING
1..100
5399
PRICE GROWTH RATING
1..100
5949
P/E GROWTH RATING
1..100
86100
SEASONALITY SCORE
1..100
n/a50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

KRYS's Valuation (65) in the Pharmaceuticals Major industry is in the same range as VRDN (95) in the Biotechnology industry. This means that KRYS’s stock grew similarly to VRDN’s over the last 12 months.

KRYS's Profit vs Risk Rating (39) in the Pharmaceuticals Major industry is somewhat better than the same rating for VRDN (93) in the Biotechnology industry. This means that KRYS’s stock grew somewhat faster than VRDN’s over the last 12 months.

KRYS's SMR Rating (53) in the Pharmaceuticals Major industry is somewhat better than the same rating for VRDN (99) in the Biotechnology industry. This means that KRYS’s stock grew somewhat faster than VRDN’s over the last 12 months.

VRDN's Price Growth Rating (49) in the Biotechnology industry is in the same range as KRYS (59) in the Pharmaceuticals Major industry. This means that VRDN’s stock grew similarly to KRYS’s over the last 12 months.

KRYS's P/E Growth Rating (86) in the Pharmaceuticals Major industry is in the same range as VRDN (100) in the Biotechnology industry. This means that KRYS’s stock grew similarly to VRDN’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
KRYSVRDN
RSI
ODDS (%)
N/A
N/A
Stochastic
ODDS (%)
Bearish Trend 1 day ago
83%
Bullish Trend 1 day ago
77%
Momentum
ODDS (%)
Bullish Trend 1 day ago
79%
Bearish Trend 1 day ago
87%
MACD
ODDS (%)
Bullish Trend 1 day ago
79%
Bearish Trend 1 day ago
87%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
78%
Bearish Trend 1 day ago
88%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
79%
Bullish Trend 1 day ago
83%
Advances
ODDS (%)
Bullish Trend 15 days ago
78%
Bullish Trend 9 days ago
81%
Declines
ODDS (%)
Bearish Trend 1 day ago
75%
Bearish Trend 3 days ago
85%
BollingerBands
ODDS (%)
Bullish Trend 1 day ago
80%
Bearish Trend 1 day ago
90%
Aroon
ODDS (%)
Bullish Trend 1 day ago
74%
Bullish Trend 1 day ago
85%
View a ticker or compare two or three
Interact to see
Advertisement
KRYS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
VRDN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
QICLX17.35N/A
N/A
AQR International Multi-Style I
FTUTX59.35N/A
N/A
Fidelity Advisor Telecommunications M
PLFMX32.05N/A
N/A
Principal Large Cap S&P 500 Index R3
WESWX11.48N/A
N/A
TETON Westwood Equity AAA
FPKFX17.43N/A
N/A
Fidelity Puritan K6

KRYS and

Correlation & Price change

A.I.dvisor indicates that over the last year, KRYS has been loosely correlated with XNCR. These tickers have moved in lockstep 52% of the time. This A.I.-generated data suggests there is some statistical probability that if KRYS jumps, then XNCR could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To KRYS
1D Price
Change %
KRYS100%
-0.17%
XNCR - KRYS
52%
Loosely correlated
+7.31%
VRDN - KRYS
50%
Loosely correlated
-0.21%
CRNX - KRYS
49%
Loosely correlated
+0.29%
ACLX - KRYS
49%
Loosely correlated
-1.20%
CGON - KRYS
48%
Loosely correlated
+5.48%
More